Small-Molecule Mitofusin Activators with Favorable Pharmacokinetics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing small molecule mitofusin activators have poor pharmacokinetic characteristics and are 'undruggable', failing to effectively stimulate mitochondrial fusion and subcellular transport, which are crucial for treating neurodegenerative diseases and disorders.
Innovation Solution
Development of a structurally distinct class of small molecule mitofusin activators that allosterically activate mitochondrial fusion and subcellular transport, including peptidomimetic compounds that mimic the chemico-structural features of mitofusin-derived peptides, enhancing mitochondrial elongation and correcting cellular dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing small molecule mitofusin activators are used, then mitochondrial fusion and subcellular transport are stimulated, but pharmacokinetic characteristics are poor making them undruggable
Solution Approach 1:
The patent modifies the chemical structure of mitofusin activators by changing molecular parameters such as adding polar groups (hydroxyl, carboxyl, amino groups) and adjusting molecular weight to fall within specific ranges (300-800 Da). These parameter changes improve pharmacokinetic properties including solubility, stability, and oral bioavailability while maintaining the ability to stimulate mitochondrial fusion through allosteric activation of mitofusin proteins.
Solution Approach 2:
The invention introduces specific functional groups at particular positions on the mitofusin activator molecules to enhance drug-like properties. By locally modifying specific regions of the molecule with polar groups or specific structural motifs, the patent improves pharmacokinetic characteristics such as membrane permeability and metabolic stability without compromising the core mitofusin activation function.
2Ease of manufacture
If structurally distinct small molecule mitofusin activators are developed, then favorable pharmacokinetic properties are achieved, but functional potency compared to existing compounds needs verification
Solution Approach 1:
The patent employs peptidomimetic compounds that copy the chemico-structural features of mitofusin-derived peptides. These synthetic molecules replicate the key structural elements and binding motifs of natural peptides that activate mitofusin, thereby preserving functional potency. The peptidomimetic approach maintains the biological activity of the original peptide while improving pharmacokinetic properties through non-peptide structural frameworks.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new mitofusin activators demonstrate favorable pharmacokinetic properties and effectively stimulate mitochondrial fusion and transport, reversing mitochondrial defects and promoting nerve repair and regeneration in neurodegenerative conditions.
Implementation Method 1
Development of a structurally distinct class of small molecule mitofusin activators that allosterically activate mitochondrial fusion and subcellular transport
Data Source
AI summary
Compositions including small molecule mitofusin activators are described. The mitofusin activators are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (MFN1) and/or mitofusin 2 (MFN2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that activate mitochondrial fusion are also described.